Taken together, our data indicate that the ATOX1 expression level can be used as a biomarker in early stages of breast cancer, whereby high ATOX1 levels correlate with worse survival prognosis in Luminal A, Luminal B and Normal-like (and Claudin low when considering OS data) tumors. Here, ATOX1 is linked to breast carcinoma.